Moderna (MRNA) is trading higher as investors continue to digest its early-May Q1 2026 results and business update, which reiterated the company’s 2026 framework and emphasized a shift toward a more balanced U.S./international revenue mix. The stock’s move also reflects a modest rebound after the immediate post-earnings volatility, with traders focusing on operational discipline and cost reductions rather than one-time items.

The latest quarterly update underscored that Moderna is still targeting up to 10% revenue growth in 2026 and highlighted international strength as a central pillar of that outlook. Management also pointed to a lower cost trajectory (including a cash-cost target that has been featured as a major internal focus), helping support sentiment even as the company remains loss-making on a GAAP basis.

Near-term attention is shifting to Moderna’s scheduled May conference appearances, which can reset expectations if the company provides incremental color on commercial execution, pipeline timing, or launch readiness across respiratory and oncology programs. Investors will also watch whether the stock can hold gains as the market refocuses from “beat-and-reiterate” headlines to the pace of demand normalization and any pipeline catalysts discussed in public forums.